https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/365 2026-07-24T01:14:04Z 2026-07-24T01:14:04Z Won, Chong Hyun Park, Chun Wook Ahn, Jiyoung Ko, Joo Yeon Cho, Sang Hyun Lee, Yang Won Lee, Joo Hee Ng, Khai Jing Hong, Min Young Zhong, Jinglin Dossenbach, Martin Son, Sang Wook https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/214437 2026-06-23T05:00:16Z 2026-06-01T00:00:00Z

Title: Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria Authors: Won, Chong Hyun; Park, Chun Wook; Ahn, Jiyoung; Ko, Joo Yeon; Cho, Sang Hyun; Lee, Yang Won; Lee, Joo Hee; Ng, Khai Jing; Hong, Min Young; Zhong, Jinglin; Dossenbach, Martin; Son, Sang Wook Abstract: Background Lebrikizumab is approved to treat patients with moderate-to-severe atopic dermatitis (AD). Objectives This study evaluated the 16-week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement-like criteria. Methods This was a post-hoc analysis of pooled data from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). Patients were randomised 2:1 to receive lebrikizumab or placebo every 2 weeks. Two non-mutually exclusive subgroups were selected based on South Korean reimbursement-like criteria: Eczema Area and Severity Index (EASI) score >= 23, AD duration >= 3 years, and previous use of any systemic treatment (ST subgroup) or previous treatment with cyclosporine or methotrexate (CM subgroup). Week-16 outcomes were Investigator's Global Assessment score of 0 or 1 (IGA [0,1]) with >= 2-point improvement, >= 50%/75%/90% improvement in EASI score (EASI 50/75/90), Pruritus Numeric Rating Scale (NRS) >= 4-point improvement, and Dermatology Life Quality Index (DLQI) >= 4-point improvement. Response rates to lebrikizumab and placebo were analysed using Cochran-Mantel-Haenszel tests. Common risk differences and 95% confidence intervals were reported. Results The ST subgroup included 322 patients, and the CM subgroup included 111 patients. More lebrikizumab-treated than placebo-treated patients achieved outcome responses. Percentage differences in favour of lebrikizumab (p < 0.01) were: IGA (0,1): ST = 25.7% (18.2%-33.1%), CM = 20.8% (7.9%-33.7%); EASI 50: ST = 42.7% (32.5%-52.9%), CM = 36.9% (19.8%-54.0%); EASI 75: ST = 40.2% (31.4%-49.1%), CM = 33.3% (19.1%-47.5%); EASI 90: ST = 27.4% (20.3%-34.5%), CM = 22.1% (11.3%-32.8%); Pruritus NRS >= 4-point improvement: ST = 34.7% (26.7%-42.7%), CM = 26.7% (14.9%-38.4%); and DLQI >= 4-point improvement: ST = 44.2% (33.2%-55.2%), CM = 39.5% (20.2%-58.8%). Conclusions In this post-hoc, exploratory subgroup analysis, lebrikizumab improved AD skin and pruritus at week 16 in adults and adolescents who would be eligible for treatment based on South Korean reimbursement-like criteria.

2026-06-01T00:00:00Z 주민숙 https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/218560 2026-07-22T23:33:56Z 2026-05-30T00:00:00Z

Title: How to assess hair loss disease Authors: 주민숙

2026-05-30T00:00:00Z 주민숙 https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/218559 2026-07-22T23:33:54Z 2026-05-28T00:00:00Z

Title: Improving SALT scoring accuracy in medical students and dermatology residents through computer-based drawing training (DermSALTTrainer) Authors: 주민숙

2026-05-28T00:00:00Z 주민숙 https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/218558 2026-07-22T23:33:53Z 2026-05-28T00:00:00Z

Title: Therapeutic dilemma of scarring alopecia in discoid lupus erythematosus: Unsatisfactory response to conventional treatment Authors: 주민숙

2026-05-28T00:00:00Z